Pharming Group N.V. (PHAR) Non-Current Deferred Tax Liability (2019 - 2024)

Pharming (PHAR) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with -$30.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-Current Deferred Tax Liability fell 2.63% year-over-year to -$30.5 million, compared with a TTM value of -$30.5 million through Dec 2024, down 2.63%, and an annual FY2024 reading of -$30.5 million, down 2.63% over the prior year.
  • Non-Current Deferred Tax Liability was -$30.5 million for Q4 2024 at Pharming, down from -$29.8 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at -$21.2 million in Q4 2021 and bottomed at -$30.9 million in Q4 2020.
  • Average Non-Current Deferred Tax Liability over 4 years is -$28.1 million, with a median of -$30.2 million recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 31.45% in 2021, then dropped 2.63% in 2024.
  • Year by year, Non-Current Deferred Tax Liability stood at -$30.9 million in 2020, then surged by 31.45% to -$21.2 million in 2021, then crashed by 40.28% to -$29.8 million in 2023, then fell by 2.63% to -$30.5 million in 2024.
  • Business Quant data shows Non-Current Deferred Tax Liability for PHAR at -$30.5 million in Q4 2024, -$29.8 million in Q4 2023, and -$21.2 million in Q4 2021.